Barclays upgraded Quest Diagnostics (DGX) to Overweight from Equal Weight with a price target of $210, up from $195. The company has “laid to rest” fears about the durability of its fundamentals as it has sustainably grown 4% organically from fiscal 2024 to 2025, the analyst tells investors in a research note. The firm sees “ample upside” to Quest’s earnings growth estimates for 2026 and potential for valuation expansion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics upgraded to Overweight from Equal Weight at Barclays
- Quest Diagnostics targets about $1.0B in dividend over 2025-2027 period
- Quest Diagnostics Highlights Growth Strategy at Healthcare Conference
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 11
- Quest Diagnostics, Corewell Health complete lab joint venture transaction